Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
January 18, 2022 08:00 ET
|
Celularity, Inc.
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase...
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
December 27, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
December 13, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically...
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
November 29, 2021 08:00 ET
|
Celularity, Inc.
CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics Phase 1/2a clinical trial will evaluate the safety and...
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
November 15, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human...
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
November 12, 2021 16:05 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
September 20, 2021 08:00 ET
|
Celularity, Inc.; Oncternal Therapeutics, Inc.
FLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived...
Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President
September 15, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today...
Celularity Reports Second Quarter 2021 Financial Results
August 16, 2021 17:15 ET
|
Celularity, Inc.
Secured funding of approximately $138 million through merger and private placement investment in public equity (PIPE) financingExpanded Phase 1 clinical trial to include difficult-to-treat patient...
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
August 04, 2021 19:00 ET
|
Celularity, Inc.
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR)...